The world is moving towards precision medicine for cancer. This movement goes hand in hand with the development of newer advanced technologies for early, precise diagnosis of cancer and personalized treatment plans with fewer adverse effects for the patient. Liquid biopsy is one such advancement. At the same time, it has the advantage of minimal invasion and avoids serial invasive biopsies. In countries with limited access to pathology services, such as sub-Saharan Africa, liquid biopsy may provide an opportunity for early detection and prognostication of lymphoma. We discuss the current diagnostic modalities for lymphoma, highlighting the existing challenges with tissue biopsy, and how feasible it is for countries with limited pathology resources to leverage advancements made in the clinical application of liquid biopsy to improve lymphoma care.

世界正在走向癌症精准医学。这一运动与更新的先进技术的发展齐头并进，以实现癌症的早期、精确诊断和个性化治疗计划，从而减少对患者的不良影响。液体活检就是这样的进步之一。同时具有微创优势，避免连续侵入性活检。在病理学服务有限的国家，例如撒哈拉以南非洲，液体活检可能为淋巴瘤的早期检测和预测提供机会。我们讨论了当前淋巴瘤的诊断方式，强调了组织活检所面临的挑战，以及病理学资源有限的国家利用液体活检临床应用取得的进步来改善淋巴瘤护理的可行性。